Sarepta price target lowered to $139 from $144 at Credit Suisse

Credit Suisse analyst Judah Frommer lowered the firm’s price target on Sarepta to $139 from $144 and keeps a Neutral rating on the shares. On Thursday, Sarepta announced that at its late cycle meeting for the SRP-9001 biologics license application, the FDA will hold an advisory committee for SRP-9001 following mid-cycle communication that seemed to definitively indicate an AdCom would not take place. The firm expects volatility stemming from the tone of briefing document content and questions the, AdCom vote, and the PDUFA.